InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

Invex Therapeutics Ltd (ASX: IXC) - Announcements

- Current share price for IXC : $0.110

ASX company news and announcements for Invex Therapeutics Ltd (IXC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Invex Therapeutics Ltd (IXC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Invex Therapeutics Ltd (IXC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Invex Therapeutics Ltd (IXC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$8 Investor Presentation 22 Nov 2022 1:05PM $0.550 $0.110 fallen by 80%
$8 Results of Meeting 22 Nov 2022 1:03PM $0.550 $0.110 fallen by 80%
$8 AGM Presentation 22 Nov 2022 11:38AM $0.550 $0.110 fallen by 80%
$8 AGM Chairmans Address 22 Nov 2022 11:33AM $0.550 $0.110 fallen by 80%
$8 First Patient Randomised in IIH EVOLVE Phase III Trial 21 Nov 2022 8:18AM $0.570 $0.110 fallen by 80.70%
$8 Invex Receives $0.46 Million R&D Tax Rebate 1 Nov 2022 8:50AM $0.560 $0.110 fallen by 80.36%
$8 Quarterly Activities/Appendix 4C Cash Flow Report 27 Oct 2022 8:17AM $0.600 $0.110 fallen by 81.67%
$8 Upcoming Presentation at Argonaut Biotech Briefing 26 Oct 2022 1:35PM $0.600 $0.110 fallen by 81.67%
$8 September Appendix 4C and Investor Conference Call Details 24 Oct 2022 12:18PM $0.600 $0.110 fallen by 81.67%
$8 First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial 24 Oct 2022 9:21AM $0.590 $0.110 fallen by 81.36%
$8 First Australian Site Activated in IIH EVOLVE Phase 3 24 Oct 2022 8:17AM $0.590 $0.110 fallen by 81.36%
$8 Notice of Annual General Meeting/Proxy Form 21 Oct 2022 12:28PM $0.590 $0.110 fallen by 81.36%
$8 Second HREC Approval for IIH EVOLVE Phase III Clinical Trial 30 Sep 2022 8:51AM $0.590 $0.110 fallen by 81.36%
$8 Date of AGM and Director Nominations 23 Sep 2022 10:35AM $0.600 $0.110 fallen by 81.67%
$8 Invex to Present at Virtual ASX Small and Mid-Cap Conference 12 Sep 2022 8:10AM $0.580 $0.110 fallen by 81.03%
$8 Appendix 4G 19 Aug 2022 9:52AM $0.560 $0.110 fallen by 80.36%
$8 Corporate Governance Statement 19 Aug 2022 9:52AM $0.560 $0.110 fallen by 80.36%
$8 4E and Annual Report to shareholders 19 Aug 2022 9:37AM $0.560 $0.110 fallen by 80.36%
$8 Invex receives IND approval 19 Aug 2022 9:25AM $0.560 $0.110 fallen by 80.36%
$8 Trading Halt 18 Aug 2022 9:37AM $0.560 $0.110 fallen by 80.36%
$8 Quarterly Activities/Appendix 4C Cash Flow Report 6 Jul 2022 9:57AM $0.480 $0.110 fallen by 77.08%
$8 HREC and TGA Approval to Commence Phase 3 in Australia 4 Jul 2022 8:46AM $0.485 $0.110 fallen by 77.32%
$8 Appendix 4C and Investor Conference Call Details 1 Jul 2022 11:04AM $0.505 $0.110 fallen by 78.22%
$8 Invex Receives UK Approval to Commence Phase III Trial 29 Jun 2022 8:29AM $0.445 $0.110 fallen by 75.28%
$8 Upcoming Presentations to the 15th EUNOS Meeting 20 Jun 2022 10:31AM $0.485 $0.110 fallen by 77.32%

126 - 150 of 300 results

Page 6 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.